TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03167957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Encochleated Amphotericin B (CAMB)
Description: Lipid-crystal nano-particle formulation amphotericin B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Encochleated Amphotericin B (CAMB)
Description: Lipid-crystal nano-particle formulation amphotericin B
Study: NCT02718807

Intervention type: OTHER
Intervention: RP model explanation and questionnaire
Description: Rapid prototyping models of anatomy will be used to demonstrate an anatomic and medical condition and participants will grade the experience on a questionnaire.

Intervention type: OTHER
Intervention: RP model explanation and questionnaire
Description: Rapid prototyping models of anatomy will be used to demonstrate an anatomic and medical condition and participants will grade the experience on a questionnaire.
Study: NCT03938038

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serial ultrasound assessments for GDT
Description: routine ultrasound assessments of volume status and fluid responsiveness for goal-directed therapy (GDT)-based fluid resuscitation

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serial ultrasound assessments for GDT
Description: routine ultrasound assessments of volume status and fluid responsiveness for goal-directed therapy (GDT)-based fluid resuscitation

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Close hemodynamic cardiac monitoring and volume responsiveness assessment on an unscheduled basis to aid physicians in resuscitation feedback

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Close hemodynamic cardiac monitoring and volume responsiveness assessment on an unscheduled basis to aid physicians in resuscitation feedback
Study: NCT01464125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosmidomycin
Description: Fosmidomycin sodium capsules 450 mg x 4 twelve-hourly for three days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin capsules 250 mg x 3 twelve-hourly for three days
Study: NCT02849340

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryosurgery
Description: Percutaneous ablation under CT or ultrasound guidance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Percutaneous ablation under CT or ultrasound guidance

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK immunotherapy
Description: Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
Study: NCT01161901

Intervention type: PROCEDURE
Intervention: blood sample
Description: This study's hypothesis is that patients with ARDS criteria and lobar morphology on CT scan present loss of aeration but no inflammatory pulmonary oedema, whereas patients with non lobar morphology on CT scan present both characteristics.~The primary purpose of our protocol is to show that the patients who respond to ARDS criteria and have a lobar morphology on CT scan do not have an elevation of the biomarkers specific to the pulmonary aggression of ARDS.
Study: NCT02685553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIR
Description: Laparoscopic use of NIR
Study: NCT00525889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Administered by subcutaneous injection at a dose of 4.5x10\^6 IU/day, three times weekly for 28 days starting on day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Administered orally, initial daily dose of 2mg. At day 7, dose adjusted to achieve and maintain whole blood trough levels of 5-10 ng/ml.
Study: NCT01835197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: Subjects will receive single doses of 3, 10, 30, 100, 200, 400, or 800 mg of PF-04695842 (solution or suspension) in a dose escalation format.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive single doses of PF-04695842 matching placebo (solution or suspension) in a dose escalation format.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: Subjects will receive doses of 30, 100 or 200 mg (solution or suspension) once daily for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive PF-04965842 matching placebo (solution or suspension) once daily for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: Subjects will receive doses of 100 or 200 mg (suspension or solution) twice daily for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive PF-04965842 matching placebo doses (suspension or solution) twice daily for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: Subjects will receive 200 mg dose (suspension or solution) twice daily for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive PF-04965842 matching placebo dose (suspension or solution) twice daily for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: Subjects will receive 400 mg dose (suspension or solution) once daily for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive PF-04965842 matching placebo dose (suspension or solution) once daily for 10 days.
Study: NCT00807963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: recombinant human hyaluronidase PH20 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: recombinant human hyaluronidase PH20 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: recombinant human hyaluronidase PH20 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: subcutaneous injection
Study: NCT01479114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rh-GCSF
Description: 10 ug/kg/day intravenously for 3 days
Study: NCT02637115

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Consumption of one dose-sachet per day. This dose-sachet contains a placebo (PBS/Glycerol)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Live Akk 9
Description: Consumption of one dose-sachet per day. This dose-sachet contains Live Akkermansia muciniphila (one billion per dose-sachet)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Live Akk 10
Description: Consumption of one dose-sachet per day. This dose-sachet contains Live Akkermansia muciniphila (ten billion per dose-sachet)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Killed Akk
Description: Consumption of one dose-sachet per day. This dose-sachet contains heat-killed Akkermansia muciniphila
Study: NCT03509896

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study: NCT01418651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savella
Description: milnacipran 25 to 200 mg daily, divided into two doses (morning and evening)
Study: NCT00129623

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po monthly for 1 year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate [Bonviva/Boniva]
Description: 150mg po monthly for 1 year
Study: NCT00450658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HZT-501
Description: HZT-501: Ibuprofen 800mg/famotidine 26.6mg orally 3 times daily for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 800mg orally 3 times daily for 24 weeks
Study: NCT04592913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Human monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLOT chemotherapy
Description: A combination treatment made up of flurouroacil + leucovorin + oxaliplatin + docetaxel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FLOT chemotherapy
Description: A combination treatment made up of flurouroacil + leucovorin + oxaliplatin + docetaxel
Study: NCT03220477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered at 200mg IV on day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Guadecitabine will be administered subcutaneously given daily on days 1-5 of each cycle with escalating doses by cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mocetinostat
Description: Mocetinostat will be administered orally with escalating doses on days 8, 10, 13, 15, 17 and 20 of each cycle with escalating doses by cohort.
Study: NCT01842386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Subjects will receive intravenous (IV) infusions of rituximab 1 gram on days 1 and 15, and subsequently if indicated up to once a month for 5 months (+/-5 days for each visit) starting approximately on day 42. Subjects whose infections respond positively to the treatment but then relapse may be offered additional treatment.
Study: NCT03589690

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha lipoic acid
Description: 22 Patients will consume 600 mg Alpha lipoic acid for 12 weeks .

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be supplemented with 600 mg/day placebo (Starch).
Study: NCT00536809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: onced daily Days 1-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Day one of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Day one of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: given BID days 1-14
Study: NCT00460174

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 10 mg/kg every 2 weeks as an intravenous infusion after gemcitabine and before radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1000 mg/m2, 30 minute intravenous infusion, cycle 1 (weeks 1, 2), cycle 2 (weeks 4, 5, 6) and cycle 3 (weeks 8 and 9). During cycle 2, gemcitabine will be delivered prior to radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: If resectable, patients will undergo surgery no less than 6 weeks following last dose of bevacizumab. Unresectable patients will not undergo surgery.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 2.4 Gy fractions, 5 fractions/week during cycle 2 only (weeks 4, 5, 6). Total dose 36 Gy.
Study: NCT02724124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static Stretching
Description: 3 sets of 30-second self static hamstring stretch (IT), quadriceps (QD) and sural triceps (TS) of both lower limbs, with an interval of 30 seconds of rest between sets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: warm up
Description: Warm-up for 10 minutes at 70-80% of maximum heart rate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: static stretching + warm up
Description: 3 sets of 30-second self static hamstring stretch (IT), quadriceps (QD) and sural triceps (TS) of both lower limbs, with an interval of 30 seconds of rest between sets + Warm-up for 10 minutes at 70-80% of maximum heart rate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: warm up+static stretching
Description: Warm-up for 10 minutes at 70-80% of maximum heart rate + 3 sets of 30-second self static hamstring stretch (IT), quadriceps (QD) and sural triceps (TS) of both lower limbs, with an interval of 30 seconds of rest between sets

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No intervention
Study: NCT01353625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-115
Description: Part A (actively recruiting): Dose level starts with 0.5mg daily by mouth in cycles of 28 days. Level increases for different patient cohorts in 100% or 50% increments until optimal dose schedule is established for further study. Treatment continues for as long as patient benefits (i.e., until disease progression or unacceptable toxicity).~Part B: Optimal dose schedule is administered in 28-day cycles until disease progression.
Study: NCT01245634

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: iv infusion every 4 weeks, 32 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4905417
Description: 20 mg/kg iv infusion every 4 weeks, 32 weeks
Study: NCT04029350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Combined With Osimertinib
Description: Anlotinib：12mg/capsule, take once when limosis in the morning. If patients suffer from AEs, they can get declined dosage (10mg or 8mg).~Osimertinib：80 mg/tablet， per os (p.o.) daily. It should be continued until disease progression or intolerable toxicity or patients withdraw of consent.
Study: NCT03954574

Intervention type: DIAGNOSTIC_TEST
Intervention: assessment of pulmonary hemodynamics during exercise by right heart catheterization
Description: all patients undergo right heart catheterization during exercise due to clinical reasons. Results of this and other Routine clinical tests will be included in the registry

Intervention type: DIAGNOSTIC_TEST
Intervention: assessment of pulmonary hemodynamics during exercise by right heart catheterization
Description: all patients undergo right heart catheterization during exercise due to clinical reasons. Results of this and other Routine clinical tests will be included in the registry
Study: NCT03180749

Intervention type: OTHER
Intervention: Follow up per standard of care
Description: Patients will come in 2 years post implantation and receive standard examinations
Study: NCT03715023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC786
Description: PC786 suspension for inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC
Description: Standard treatment for RSV infection at study site

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SOC
Description: Standard treatment for RSV infection at study site
Study: NCT00668278

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of I-gel airway
Description: Insertion of I-gel airway under anaesthesia; Fentanyl 1-2mcg/kg; Propofol 1-3mg/kg; Atracurium 0.5mg/kg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of airway pressures
Description: Measurement of peak airway pressure under steady state; measurement of device seal pressure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of airway pressures
Description: Measurement of peak airway pressure under steady state; measurement of device seal pressure
Study: NCT01096355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Study: NCT00528866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide
Description: 50 mg (one tablet) daily orally for 6 months, starting within 6 months after registration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 75 mg/m2 IV over 1 hour on day 1 of each cycle q21 days for 6 cycles, starting 3-6 weeks after completion of radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flutamide
Description: 250 mg (two 125-mg capsules) three times daily (total 750 mg) orally for 6 months, starting within 6 months after registration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH agonist
Description: LHRH agonist (such as leuprolide, goserelin, buserelin, or triptorelin) for 6 months, starting within 6 weeks after registration

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 66.6 Gy (1.8 Gy per fraction, 5 days per week) to the prostate bed (IMRT or 3DCRT), starting 8 weeks after start of hormones
Study: NCT02202551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADS-5102
Study: NCT02888665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT04092972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Atherectomy
Description: Straub Rotarex S atherectomy and drug-coated balloon DCB. Predilation of the lesion with a predefined ballon (180 sec, Passeo-18). Thus, no direct DCB will be conducted. All DCB lengths (40mm to 200 mm) and Diameters (3mm to 7mm) are eligible for the Trial as long as used in the superficial femoral artery (SFA).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: POBA and DCB
Description: Standard predilation (POBA) and DCB. Predilation of the lesion with a predefined ballon (180 sec, Passeo-18). Thus, no direct DCB will be conducted. All DCB lengths (40mm to 200 mm) and Diameters (3mm to 7mm) are eligible for the Trial as long as used in the superficial femoral artery (SFA).
Study: NCT03607123

Intervention type: OTHER
Intervention: programing of pacemaker
Description: Different programing parameters will be set in different group/stage

Intervention type: OTHER
Intervention: programing of pacemaker
Description: Different programing parameters will be set in different group/stage

Intervention type: OTHER
Intervention: programing of pacemaker
Description: Different programing parameters will be set in different group/stage

Intervention type: PROCEDURE
Intervention: AF ablation
Description: AF ablation can only be performed in Step 3

Intervention type: PROCEDURE
Intervention: AF ablation
Description: AF ablation can only be performed in Step 3

Intervention type: PROCEDURE
Intervention: AF ablation
Description: AF ablation can only be performed in Step 3

Intervention type: DRUG
Intervention: Anti arryhthmic drugs
Description: Anti arryhthmic drugs can be prescribed in Step 2, Step3 and SAFE PAF-SND
Study: NCT02505581

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extra dosage - cefuroxime (750mg) I.V
Description: In both groups a second intravenous dose of cefuroxime (750mg) will be administered if the intraoperative time elongates more than three hours or there is an intraoperative bleeding over 1000cc

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extra dosage - cefuroxime (750mg) I.V
Description: In both groups a second intravenous dose of cefuroxime (750mg) will be administered if the intraoperative time elongates more than three hours or there is an intraoperative bleeding over 1000cc

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colorectal Surgery
Description: Both groups undergo colorectal surgery. This section does not include rectal surgery ( see Inclusion/exclusion criteria)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colorectal Surgery
Description: Both groups undergo colorectal surgery. This section does not include rectal surgery ( see Inclusion/exclusion criteria)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg oral
Description: An oral antibiotic pattern of ciprofloxacin (750 mg / 12h, 2 doses) the day before surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole 250 mg oral
Description: An oral antibiotic pattern of metronidazole (250 / 8h, 3 doses) the day before surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefuroxime 1.5 g Intravenous
Description: An intravenous antibiotic pattern of cefuroxime 1.5 g during anesthetic induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefuroxime 1.5 g Intravenous
Description: An intravenous antibiotic pattern of cefuroxime 1.5 g during anesthetic induction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole 1 g Intravenous
Description: An intravenous antibiotic pattern of metronidazole 1 g during anesthetic induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole 1 g Intravenous
Description: An intravenous antibiotic pattern of metronidazole 1 g during anesthetic induction.
Study: NCT00400309

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REPEVAX® after REVAXIS®
Description: Tetanus, diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine after tetanus, diphtheria, poliomyelitis (inactivated)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: REPEVAX® after Placebo
Description: Tetanus, diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine after placebo